生物活性

• 描述Fruquintinib inhibits VEGFR family member (VEGFR1, 2, 3) with IC50s of 33 nM, 35 nM and 0.5 nM, respectively with weak inhibition of RET, FGFR-1 and c-kit kinases.
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT03223376	Advanced Gastric Cancer	Phase 3	Recruiting	December 2020	China, Anhui ... more >> Hutchison Medi Pharma Invesigational sites Not yet recruiting Hefei, Anhui, China, 230000 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    China, Guangdong Hutchison Medi Pharma Investigational Site Recruiting Guangzhou, Guangdong, China, 510030 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    Principal Investigator: Ruihua Xu, PhD,MD          China, Heilongjiang Hutchison Medi Pharma Investigational site Not yet recruiting Harbin, Heilongjiang, China, 150081 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    China, Jiangsu Huchison Medi Pharma Investigational site Not yet recruiting Nanjing, Jiangsu, China, 210000 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    China, Zhejiang Hutchison Medi Pharma Investigational sites Not yet recruiting Hangzhou, Zhejiang, China, 310000 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    China Hutchison Medi Pharma Investigational sites Not yet recruiting Beijing, China, 100142 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com    Hutchison Medi Pharma Investigational site Not yet recruiting Shanghai, China, 200125 Contact: Songhua Fan, MD    862120673058    songhuaf@hmplglobal.com Collapse <<
  NCT02196688	Colorectal Cancer	Phase 2	Completed	-	China, Beijing ... more >> Hutchison Medi Pharma Investigational Site Beijing, Beijing, China, 100071 China, Guangdong Hutchison Medi Pharma Investigational Site Guangzhou, Guangdong, China, 510060 China, Heilongjiang Hutchison Medi Pharma Ha er bin, Heilongjiang, China, 150081 China, Zhejiang Hutchison Medi Pharma Investigational Site Hangzhou, Zhejiang, China, 310016 China Hutchison Medi Pharma Investigational Site Shanghai, China, 200032 Collapse <<
  NCT02691299	NSCLC	Phase 3	Active, not recruiting	December 2018	China, Beijing ... more >> 307 Hospital of PLA Beijing, Beijing, China, 100071 Beijing Cancer Hospital Beijing, Beijing, China, 100142 Beijing Chest Hospital Beijing, Beijing, China, 101149 China, Guangdong Guangdong General Hospital Guangzhou, Guangdong, China, 510080 China, Jiangsu Nantong Tumor Hospital Nantong, Jiangsu, China, 226000 China, Jilin The First Hospital of Jilin University Changchun, Jilin, China, 130021 China, Shandong Linyi Tumor Hospital Linyi, Shandong, China, 276001 China, Shanghai The Cancer Hospital of Fudan University Shanghai, Shanghai, China, 200000 Shanghai Chest Hospital Shanghai, Shanghai, China, 200030 China, Sichuan West China Hospital Chengdu, Sichuan, China, 610041 China, Zhejiang The First Affiliated Hosptial of College of Medicine, Zhejiang University Hangzhou, Zhejiang, China, 310003 Collapse <<

• 更多
• 参考文献

• [1] Xu RH, Li J, et al. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 2017 Jan 19;10(1):22.

  [2] Sun Q, Zhou J, et al. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 2014;15(12):1635-45.